Your search history is turned on.
Date: May 5, 2021 Jurisdictions: Ontario
NT 10-K 1 formnt10k.htm FORM NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ x ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form ...
Date: December 15, 2020 Jurisdictions: Ontario
Microsoft Word - DRAFT PRESS RELEASE.docx Nerium Biotechnology Announces Resignation of Director San Antonio Texas, December 15, 2020: Nerium Biotechnology Inc. (Nerium or the Company) announces that Dan Amadori has resigned from the Board of Directors of the Company effective December 11, 2020. Mr. Amadori has served as a member of the Board since January...
Date: November 30, 2020 Jurisdictions: Ontario
Microsoft Word - NERIUM final Financial Statements for filing at 9-30-20.docx Nerium Biotechnology, Inc. Interim Condensed Consolidated Financial Statements September 30, 2020 (Unaudited) (in U.S. dollars) 2 Nerium Biotechnology, Inc. Table of Contents September 30, 2020 Page Notice to Shareholders 3 Interim Conde...
Microsoft Word - 2020 Q3 Certification - Henry Bourg.doc 1 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Henry C Bourg, Chief Financial Officer of Nerium Biotechnology, Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Nerium Biotechn...
Microsoft Word - 2020 Q3 Certification - Dennis Knocke.doc 1 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Dennis R. Knocke, Chief Executive Officer of Nerium Biotechnology, Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Nerium Bi...
Microsoft Word - NERIUM FINAL MDA @ Sept 30 2020 for filing on SEDAR.docx 1 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2020 The following managements discussion and analysis (MD&A), dated November 30, 2020, is a discussion relating to the financial results ...
Date: November 27, 2018 Jurisdictions: Ontario
Nerium Biotechnology, Inc. Interim Condensed Consolidated Financial Statements September 30, 2018 (Unaudited) (in U.S. dollars) 2 Nerium Biotechnology, Inc. Table of Contents September 30, 2018 Page Interim Condensed Consolidated Financial Statements (...
12835488.2 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Dennis R. Knocke, Chief Executive Officer of Nerium Biotechnology, Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Nerium Biotechnology, Inc. (the "issuer") for the interim per...
12835502.2 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Lori A. Jones, Chief Financial Officer of Nerium Biotechnology, Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Nerium Biotechnology, Inc. (the "issuer") for the interim period...
1 MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2018 The following managements discussion and analysis (MD&A), dated November 27, 2018, is a discussion relating to the financial results and condition of Nerium Biotechnology, Inc. (Nerium or Company) as...